Major Shareholder Announcement

Company Announcement - Genmab A/S announces that Baillie Gifford & Co holds voting rights to 3,301,530 shares, representing 4.99% of the share capital and voting rights as of October 3, 2024 [1] About Genmab - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with a vision to transform cancer treatment by 2030 [2] - The company has developed next-generation antibody technology platforms, including bispecific T-cell engagers and antibody-drug conjugates, leveraging data sciences for its proprietary pipeline [2] Company Background - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with a presence in North America, Europe, and Asia Pacific [3]